STOCK TITAN
  1. Home
  2. Sec-filings
  3. VALN
  4. [6-K] Valneva SE Current Report (Foreign Issuer)

Valneva (Nasdaq: VALN) holders approve AGM items and elect new chair

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Valneva SE reported that shareholders approved all Board-recommended resolutions at its Annual General Meeting in Lyon. Key decisions included approval of the 2025 financial statements, renewal of share capital authorizations and the transfer of the company’s registered office to Lyon.

Shareholders reappointed five directors with staggered terms, and the Board subsequently named independent director Dr. Gerd Zettlmeissl as Chair. Former Chair Anne‑Marie Graffin will remain on the Board as Vice-chair, while Valneva continues to focus on its portfolio of specialty travel and infectious disease vaccines.

Positive

  • None.

Negative

  • None.
Financial year approved 2025 financial statements AGM approval of company accounts
Director one-year terms 1-year terms Reappointments of Graffin, Sulat, Jansen
Director two-year term 2-year term Reappointment of James Connelly
Director three-year term 3-year term Reappointment of CEO Thomas Lingelbach
Industry experience more than 40 years Dr. Zettlmeissl’s biopharmaceutical experience
Annual General Meeting financial
"shareholders approved all resolutions recommended by the Board of Directors at the Company’s Annual General Meeting (AGM)"
Board of Directors financial
"renewal of authorizations granted to the Board of Directors regarding the Company’s share capital"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
registered office financial
"the transfer of Valneva’s registered office to Lyon following the closure of its Nantes site"
The registered office is a company’s official legal address where government agencies and other parties send formal notices, legal papers, and where certain company records are kept. For investors it matters because this address establishes the company’s legal jurisdiction and point of contact for regulatory filings and service of process—think of it as the company’s official mailing address and legal foothold, which affects compliance, transparency and where you can access key documents.
prophylactic vaccines medical
"develops, manufactures, and commercializes prophylactic vaccines for infectious diseases"
forward-looking statements financial
"This press release contains certain forward-looking statements relating to the business of Valneva"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
vaccine pipeline medical
"Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report: June 25, 2026

Commission File Number: 001-40377

Valneva SE
(Translation of registrant's name into English)

Îlot Saint-Joseph, Bureaux Convergence
12ter Quai Perrache
69002 Lyon, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐


On June 25, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1. The information contained in this Form 6-K is hereby incorporated by reference into the registrant's registration Statement on Form F-3 (File No. 333-268071).

Exhibit
Exhibit 99.1
Press release dated June 25, 2026










SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Valneva SE (Registrant)
Date: June 25, 2026
/s/ Thomas Lingelbach
Thomas Lingelbach
Chief Executive Officer and President



                            
Valneva Announces Successful Outcome of its
Annual General Meeting

Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors

Lyon (France), June 25, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that shareholders approved all resolutions recommended by the Board of Directors at the Company’s Annual General Meeting (AGM), held earlier today in Lyon, France.
Key resolutions adopted included the approval of the 2025 financial statements, renewal of authorizations granted to the Board of Directors regarding the Company’s share capital, and the transfer of Valneva’s registered office to Lyon following the closure of its Nantes site.
Shareholders also approved the reappointment of five Board members. Anne-Marie Graffin, James Sulat and Kathrin Jansen were reappointed for one-year terms, James Connelly for a two-year term, and Valneva’s Chief Executive Officer Thomas Lingelbach for a three-year term.
At a Board meeting held following the AGM, Dr. Gerd Zettlmeissl, an independent director, was appointed as Chair of the Board of Directors. Dr. Zettlmeissl is a vaccine expert and biotech entrepreneur with more than 40 years of scientific and leadership experience in the biopharmaceutical industry. During the last 15 years he served as chair of the Board of Directors of several non-profit vaccine organizations as well as public and private biotech companies. He succeeds Anne-Marie Graffin, who chaired the Board for the past three years and who will continue as Vice-chair of the Board.
Gerd Zettlmeissl, chair of Valneva´s Board of Directors, commented, “I am honored to be appointed chair of the Board and would like to thank Anne-Marie for her outstanding leadership during her tenure. I look forward to working closely with my fellow board colleagues and the management team to support Valneva’s strategic priorities and long-term value creation for shareholders.”
Detailed voting results will be made available in the “Investors & Media” section of Valneva’s corporate website in the coming days.

About Valneva SE
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.
Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella


vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at www.valneva.com.


Valneva Media and Investor Relations Contacts
Laetitia Bachelot-Fontaine
VP Global Communications & European Investor Relations
M +33 (0)6 4516 7099
laetitia.bachelot-fontaine@valneva.com    

Joshua Drumm, Ph.D.
VP Global Investor Relations
M +001 917 815 4520
joshua.drumm@valneva.com


Forward-Looking Statements
This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to use and regulatory review of existing products. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results or new adverse events, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


2
    

Source: View Original Filing on SEC EDGAR

FAQ

What did Valneva (VALN) announce in its June 2026 AGM update?

Valneva announced that shareholders approved all Board-recommended resolutions at the June 2026 Annual General Meeting in Lyon. These included the 2025 financial statements, renewed share capital authorizations, governance changes and the transfer of the company’s registered office from Nantes to Lyon.

Which key resolutions did Valneva (VALN) shareholders approve at the AGM?

Shareholders approved the 2025 financial statements, renewed authorizations granted to the Board regarding Valneva’s share capital and agreed to transfer the company’s registered office to Lyon. These decisions formalize prior strategic moves, including the closure of the Nantes site, and maintain financial and capital flexibility.

Who is the new Chair of Valneva (VALN)’s Board of Directors?

Independent director Dr. Gerd Zettlmeissl was appointed Chair of Valneva’s Board following the AGM. He brings more than 40 years of biopharmaceutical experience and has chaired several non-profit vaccine organizations and biotech companies. Former Chair Anne‑Marie Graffin will continue serving as Vice-chair of the Board.

Which Valneva (VALN) Board members were reappointed and for how long?

Shareholders reappointed five directors: Anne‑Marie Graffin, James Sulat and Kathrin Jansen for one-year terms, James Connelly for a two-year term and CEO Thomas Lingelbach for a three-year term. This mix of term lengths supports continuity and staggered refreshment of the Board’s composition.

What business focus did Valneva (VALN) highlight in this communication?

Valneva highlighted its role as a specialty vaccine company focused on prophylactic vaccines for infectious diseases. It currently markets three proprietary travel vaccines and is advancing a Lyme disease vaccine candidate with Pfizer, a leading Shigella vaccine candidate and other programs targeting global public health threats.

What forward-looking risks did Valneva (VALN) reference in its statement?

Valneva noted that forward-looking statements are subject to risks including vaccine development and manufacturing uncertainties, clinical trial outcomes, regulatory actions, competition, currency fluctuations, credit conditions and intellectual property protection. It cautioned that actual results may differ materially and disclaimed any obligation to update such statements.

Filing Exhibits & Attachments

1 document

Press Releases